Vitofyllin 50 mg Film-coated Tablets for Dogs

Main information

  • Trade name:
  • Vitofyllin 50 mg Film-coated Tablets for Dogs
  • Pharmaceutical form:
  • Tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Vitofyllin 50 mg Film-coated Tablets for Dogs
    France
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • PERIPHERAL VASODILATORS
  • Therapeutic area:
  • Dogs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • UK/V/0392/001
  • Authorization date:
  • 22-02-2012
  • EU code:
  • UK/V/0392/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

Issued:May2012

AN:02114/2010

Page1of5

SUMMARYOFPRODUCTCHARACTERISTICS

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Vitofyllin50mgfilm-coatedtabletsfordogs

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Activesubstance:

Propentofylline 50.00mg/tablet

Excipients:

FerricOxide,yellow,(E172) 0.075mg/tablet

TitaniumDioxide,(E171) 0.215mg/tablet

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Film-coatedtablets.

Yellow,round,convextabletswithcross-snaptabononeandimpr inting“50”ontheother

side.

Thetabletcanbedividedintoequalhalvesandquarters.

4. CLINICALPARTICULARS

4.1Targetspecies

Dogs.

4.2Indicationsforuse,specifyingthetargetspecies

Fortheimprovementofperipheralandcerebralvascularbloodcirculation.For

improvementindullness,lethargyandoveralldemeanourindogs.

4.3Contraindications

Refertosection4.7

Donotuseindogsweighinglessthan2.5kg.

Donotuseincasesofhypersensitivitytotheactivesubstanceand/ortoanyoftheother

ingredientsoftheproduct.

4.4Specialwarnings

None.

Issued:May2012

AN:02114/2010

Page2of5

4.5Specialprecautionsforuse

Specialprecautionsforuseinanimals

Specificdiseases(e.g.kidneydisease)shouldbetreatedaccordingly.

Considerationshouldbegiventorationalisingthemedicationofdogsalreadyreceiving

treatmentforcongestiveheartfailureorbronchialdisease.

Inthecaseofrenalfailure,thedoseshouldbereduced.

Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Careshouldbetakentoavoidaccidentalingestion.

Washhandsafteruse.

4.6Adversereactions(frequencyandseriousness)

Onrareoccasions,allergicskinreactions,vomitingandcardiacdisturbanceshave

beenreported.Inthesecases,thetreatmentshouldbestopped.

4.7Useduringpregnancy,lactationorlay

Donotuseinpregnantorlactatingbitchesorbreedinganimalsastheproducthasnot

beenevaluatedintheseanimals.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Noneknown.

4.9Amountstobeadministeredandadministrationroute

Thebasicdosageis6-10mgpropentofylline/kgbodyweight,dividedintotwo3-5mg/kg

dosesasfollows:

Bodyweight

(kg) Tablets Daily

total

tablets Dailytotal

dose

(mg/kg) am pm

2.5-4kg ¼ ¼ ½ 6.3-10.0

5-7kg ½ ½ 1 7.1-10.0

8 –9kg ¾ ¾ 1½ 8.3-9.4

10-15kg 1 1 2 6.7 –10.0

16-25kg 1½ 1½ 3 6.0 –9.4

26-33kg 2 2 4 6.1-7.7

Dogsofmorethan20kgcanbegivenVitofyllin100mgfilm-coatedtabletsfordogs.

Issued:May2012

AN:02114/2010

Page3of5

Thetabletscanbeadministereddirectlyontothebackofthedog'stongueorcanbe

mixedinasmallballoffoodandshouldbeadministeredatleast30minutesbefore

feeding.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Excitationtachycardia,hypotension,reddeningofmucousmembranesandvomiting.

Thewithdrawalofthetreatmentleadstoaspontaneousremissionofthesesigns.

4.11Withdrawalperiod(s)

(notapplicable)

5. PHARMACOLOGICALPROPERTIES

Pharmacotherapeuticgroup:peripheralvasodilator;purinederivatives;propentofylline

ATCvetcode:QC04AD90

5.1Pharmacodynamicproperties

Propentofyllinehasbeenshowntoincreasebloodflow,particularlyoftheheartand

skeletalmuscle.Italsoincreasesthebloodflowofthebrainandthereforeitsoxygen

supply,withoutincreasingthebrain'sglucosedemand.Ithasamodestpositive

chronotropiceffectandamarkedpositiveionotropiceffect.Inaddition,ithasbeen

showntohaveananti-arrhythmiceffectindogswithmyocardialischemiaanda

bronchodilatoractionequivalenttothatofaminofylline.

Propentofyllineinhibitsplateletaggregationandimprovestheflowpropertiesof

erythrocytes.

Ithasadirecteffectontheheartandreducesperipheralvascularresistancethereby

loweringcardiacload.

Propentofyllinemayincreasewillingnesstoexerciseandexercisetolerance,particularly

inolderdogs.

5.2Pharmacokineticparticulars

Afteroraladministrationpropentofyllineisfastandcompletelyabsorbedandquickly

distributedinthetissues.Givenorallytodogs,maximumplasmalevelsarereached

alreadyafter15minutes.

Thehalf-timeisabout30minutesandthebioavailabilityforthemothersubstance

amountstoabout30%.Thereareanumberofeffectivemetabolitesandthe

biotransformationtakesplacemainlyintheliver.Propentofyllineisexcretedinformofits

metabolitesin80-90%viathekidneys.Therestiseliminatedwiththefaeces.Thereis

noaccumulation.

Issued:May2012

AN:02114/2010

Page4of5

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Lactosemonohydrate

MaizeStarch

Crospovidone

Talc

Silica,ColloidalAnhydrous

MagnesiumStearate

FilmCoating:

TitaniumDioxide,E171

FerricOxide,yellow,E172

Hypromellose

Macrogol6000

Talc

6.2Incompatibilities

Notapplicable.

6.3Shelf-life

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:3years

Unuseddividedtabletsshouldbereturnedtotheblisterpackandanydividedtablet

portionsremainingafter72hoursshouldbediscarded.

6.4.Specialprecautionsforstorage

Storeintheoriginalpackage(blister)andkeeptheblisterpacksintheoutercartonand

storeinadryplace.Dividedtabletsshouldbestoredintheblisterpack.

6.5Natureandcompositionofimmediatepackaging

Polyvinylchloride –PolyVinylidenedichloride/Aluminiumblisterwith14tablets,ina

cardboardboxcontaining4blisters(56tablets).

Polyvinylchloride –PolyVinylidenedichloride/Aluminiumblisterwith14tablets,ina

cardboardboxcontaining10blisters(140tablets).

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinal

productorwastematerialsderivedfromtheuseofsuchproducts

Issued:May2012

AN:02114/2010

Page5of5

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuch

veterinarymedicinalproductsshouldbedisposedofinaccordancewithlocal

requirements.

7. MARKETINGAUTHORISATIONHOLDER

AnimalcareLimited

CommonRoad

Dunnington

York

YO195RU

UK

8. MARKETINGAUTHORISATIONNUMBER

Vm10347/4032

9. DATEOFFIRSTAUTHORISATION

2May2012

10.DATEOFREVISIONOFTHETEXT

May2012

6-12-2018

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma Issues Voluntary Nationwide Recall of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, Due to Potential Higher Concentrations of Ibuprofen

Tris Pharma, Inc. has voluntarily recalled three (3) lots of Infants’ Ibuprofen Concentrated Oral Suspension, USP (NSAID) 50 mg per 1.25 mL, to the retail level. The recalled lots of the product have been found to potentially have higher concentrations of ibuprofen.

FDA - U.S. Food and Drug Administration

4-12-2018

FDA Approves Pexion for Treating Noise Aversion in Dogs

FDA Approves Pexion for Treating Noise Aversion in Dogs

The U.S. Food and Drug Administration announced today that its Center for Veterinary Medicine has approved Pexion (imepitoin tablets) to treat noise aversion in dogs. Dogs with noise aversion are sensitive to loud noises such as fireworks, street/traffic noises, and gun shots.

FDA - U.S. Food and Drug Administration

19-11-2018

Certain Option and Personelle sunscreens voluntarily recalled because of bacterial contamination

Certain Option and Personelle sunscreens voluntarily recalled because of bacterial contamination

One lot each of Option Family Sunscreen Lotion SPF 50 and Personnelle Sport Sunscreen Lotion SPF 50 have been voluntarily recalled by Empack Spraytech Inc. because of bacterial contamination.

Health Canada

15-11-2018

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Safety and efficacy of Monimax® (monensin sodium and nicarbazin) for chickens for fattening and chickens reared for laying

Published on: Wed, 14 Nov 2018 The coccidiostat Monimax® (monensin sodium and nicarbazin) is considered safe for chickens for fattening and chickens reared for laying at the highest use level of 50 mg monensin and 50 mg nicarbazin/kg complete feed. This conclusion is extended to chickens reared for laying. For both active substances, the metabolic pathways in the chicken are similar to those in the turkey and rat. Nicarbazin, when ingested, is rapidly split in its two components dinitrocarbanilide (DNC)...

Europe - EFSA - European Food Safety Authority Publications

7-9-2018

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up

Camber Pharmaceuticals, Inc. is voluntarily recalling one single lot of Montelukast Sodium Tablets, USP 10mg, to the consumer level. This recall of one batch of Montelukast Sodium Tablets, USP 10mg, lot# MON17384 Exp. 12/31/2019, was prompted because a complaint of a sealed bottle labeled as Montelukast 10mg 30 ct found to contain 90 tablets of Losartan Potassium Tablets, USP 50mg

FDA - U.S. Food and Drug Administration

3-8-2018

Scientific guideline:  Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance, adopted

Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

3-8-2018

Scientific guideline:  Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Scientific guideline: Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance, adopted

Cholic acid capsules 50 mg and 250 mg product-specific bioequivalence guidance

Europe - EFSA - European Food Safety Authority EFSA Journal

17-7-2018

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

July 17, 2018: Former President of Cumberland Distribution, Inc. Sentenced to 15 Years in Federal Prison for $50 Million Drug Diversion Scheme

FDA - U.S. Food and Drug Administration

31-5-2018

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles

Apotex Corp. Issues Voluntary Nationwide Recall of Fluticasone Propionate Nasal Spray USP 50 mcg Per Spray 120 Metered Sprays Due to Potential for Small Glass Particles

Apotex Corp. is voluntarily recalling one (1) lot of Fluticasone Propionate Nasal Spray, USP, 50 mcg per spray, 120 Metered Sprays, to the consumer level. The Fluticasone Propionate Nasal Spray USP 50 mcg per spray 120 Metered Sprays has been found to contain small glass particles. The glass particles could block the actuator and impact the functionality of the pump. The issue was discovered through a customer complaint.

FDA - U.S. Food and Drug Administration

21-2-2017

Takeda Pharma A/S recalls batch of Pamol® in packs of 300 film-coated tablets

Takeda Pharma A/S recalls batch of Pamol® in packs of 300 film-coated tablets

Takeda Pharma A/S recalls a batch of Pamol® in packs of 300 film-coated tablets after the discovery of Ibumetin 600 mg containing ibuprofen in some packs. Both types of medicine are used for the treatment of mild pain, but they work in different ways and may cause different adverse reactions.

Danish Medicines Agency

26-11-2018

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009.  https

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009. https

Today, #FDA’s device center also posted performance report highlighting measures taken to increase predictability, transparency of 510(k) review process, incl. 50 final guidance documents on important medical device policy issues issued since 2009. https://go.usa.gov/xPHdn 

FDA - U.S. Food and Drug Administration